Кеймбридж
[ ]
APN01
Международное непатентованное наименование APN01
Торговое наименование -
Производитель, страна APEIRON Biologics AG, Austria
Лекарственная форма tablet, 400mg
Механизм действия

APN01 is a recombinant human angiotensin-converting enzyme 2 (ACE2) molecule. ACE2 is the receptor that the SARS-CoV-2 spike protein binds in order for the virus to gain access to host cells. This treatment is thought to act as a competitive inhibitor against the virus by binding the spike protein and preventing binding to host cell ACE2.

Публикации COVID-19

Neda Roshanravana, Samad Ghaffaria Mehdi Hedayatib. Angiotensin converting enzyme-2 as therapeutic target in COVID-19. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. Volume 14, Issue 4, July–August 2020, Pages 637-639. DOI: 10.1016/j.dsx.2020.05.022.

 

Florence Rodgers, Toby Pepperrell, et al. Missing clinical trial data: the knowledge gap in the safety of potential COVID-19 drugs. 30 May 2020. DOI: 10.1101/2020.05.30.20117523.

 

SonjaGroß, Christopher Jahn, et al. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. Journal of Molecular and Cellular Cardiology. 30 April 2020. DOI: 10.1016/j.yjmcc.2020.04.031.

 

Bonnie Ky, Douglas L.MannCOVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. JACC: Basic to Translational Science. 16 April 2020. DOI: 10.1016/j.jacbts.2020.04.003. 

 

Angeliki M.AngelidiMatthew J.BelangerChristos S.Mantzoros. COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. Metabolism. 19 April 2020, 154245. DOI: 10.1016/j.metabol.2020.154245. 

Клинические исследования
1.
Название протокола Рекомбинантный человеческий ангиотензинпревращающий фермент 2 (rhACE2) в лечении пациентов с COVID-19
Дата начала и окончания КИ June 22, 2020 - November 30, 2020
Название организации, проводящей КИ Apeiron Biologics
Страны Россия
Фаза II
Кол-во пациентов 150
2.
Название протокола Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19
Дата начала и окончания КИ April 30, 2020 - November 2020
Название организации, проводящей КИ Apeiron Biologics
Страны Austria, Denmark, Germany
Фаза II
Кол-во пациентов 200